Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer
(2021) In European Journal of Nuclear Medicine and Molecular Imaging 48(2). p.469-476- Abstract
Purpose: Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) is used for (re)staging prostate cancer (PCa) and as a biomarker for evaluating response to therapy, but lacks established response criteria. A panel of PCa experts in nuclear medicine, radiology, and/or urology met on February 21, 2020, in Amsterdam, The Netherlands, to formulate criteria for PSMA PET/CT-based response in patients treated for metastatic PCa and optimal timing to use it. Methods: Panelists received thematic topics and relevant literature prior to the meeting. Statements on how to interpret response and progression on therapy in PCa with PSMA PET/CT and when to use it were developed. Panelists voted anonymously... (More)
Purpose: Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) is used for (re)staging prostate cancer (PCa) and as a biomarker for evaluating response to therapy, but lacks established response criteria. A panel of PCa experts in nuclear medicine, radiology, and/or urology met on February 21, 2020, in Amsterdam, The Netherlands, to formulate criteria for PSMA PET/CT-based response in patients treated for metastatic PCa and optimal timing to use it. Methods: Panelists received thematic topics and relevant literature prior to the meeting. Statements on how to interpret response and progression on therapy in PCa with PSMA PET/CT and when to use it were developed. Panelists voted anonymously on a nine-point scale, ranging from strongly disagree (1) to strongly agree (9). Median scores described agreement and consensus. Results: PSMA PET/CT consensus statements concerned utility, best timing for performing, criteria for evaluation of response, patients who could benefit, and handling of radiolabeled PSMA PET tracers. Consensus was reached on all statements. PSMA PET/CT can be used before and after any local and systemic treatment in patients with metastatic disease to evaluate response to treatment. Ideally, PSMA PET/CT imaging criteria should categorize patients as responders, patients with stable disease, partial response, and complete response, or as non-responders. Specific clinical scenarios such as oligometastatic or polymetastatic disease deserve special consideration. Conclusions: Adoption of PSMA PET/CT should be supported by indication for appropriate use and precise criteria for interpretation. PSMA PET/CT criteria should categorize patients as responders or non-responders. Specific clinical scenarios deserve special consideration.
(Less)
- author
- publishing date
- 2021
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Monitoring, Oligometastatic prostate cancer, PERCIST, PET/CT, Polymetastatic prostate cancer, Prostate cancer, Prostate-specific membrane antigen (PSMA), PSMA ligand, RECIST
- in
- European Journal of Nuclear Medicine and Molecular Imaging
- volume
- 48
- issue
- 2
- pages
- 469 - 476
- publisher
- Springer
- external identifiers
-
- scopus:85087447530
- pmid:32617640
- ISSN
- 1619-7070
- DOI
- 10.1007/s00259-020-04934-4
- language
- English
- LU publication?
- no
- id
- fec2391a-a5df-4e67-a3eb-96a1d3cc6a8a
- date added to LUP
- 2020-07-20 12:36:02
- date last changed
- 2024-06-13 20:12:13
@article{fec2391a-a5df-4e67-a3eb-96a1d3cc6a8a,
abstract = {{<p>Purpose: Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) is used for (re)staging prostate cancer (PCa) and as a biomarker for evaluating response to therapy, but lacks established response criteria. A panel of PCa experts in nuclear medicine, radiology, and/or urology met on February 21, 2020, in Amsterdam, The Netherlands, to formulate criteria for PSMA PET/CT-based response in patients treated for metastatic PCa and optimal timing to use it. Methods: Panelists received thematic topics and relevant literature prior to the meeting. Statements on how to interpret response and progression on therapy in PCa with PSMA PET/CT and when to use it were developed. Panelists voted anonymously on a nine-point scale, ranging from strongly disagree (1) to strongly agree (9). Median scores described agreement and consensus. Results: PSMA PET/CT consensus statements concerned utility, best timing for performing, criteria for evaluation of response, patients who could benefit, and handling of radiolabeled PSMA PET tracers. Consensus was reached on all statements. PSMA PET/CT can be used before and after any local and systemic treatment in patients with metastatic disease to evaluate response to treatment. Ideally, PSMA PET/CT imaging criteria should categorize patients as responders, patients with stable disease, partial response, and complete response, or as non-responders. Specific clinical scenarios such as oligometastatic or polymetastatic disease deserve special consideration. Conclusions: Adoption of PSMA PET/CT should be supported by indication for appropriate use and precise criteria for interpretation. PSMA PET/CT criteria should categorize patients as responders or non-responders. Specific clinical scenarios deserve special consideration.</p>}},
author = {{Fanti, Stefano and Goffin, Karolien and Hadaschik, Boris A. and Herrmann, Ken and Maurer, Tobias and MacLennan, Steven and Oprea-Lager, Daniela E. and Oyen, Wim Jg and Rouvière, Olivier and Mottet, Nicolas and Bjartell, Anders}},
issn = {{1619-7070}},
keywords = {{Monitoring; Oligometastatic prostate cancer; PERCIST; PET/CT; Polymetastatic prostate cancer; Prostate cancer; Prostate-specific membrane antigen (PSMA); PSMA ligand; RECIST}},
language = {{eng}},
number = {{2}},
pages = {{469--476}},
publisher = {{Springer}},
series = {{European Journal of Nuclear Medicine and Molecular Imaging}},
title = {{Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer}},
url = {{http://dx.doi.org/10.1007/s00259-020-04934-4}},
doi = {{10.1007/s00259-020-04934-4}},
volume = {{48}},
year = {{2021}},
}